Hoth Therapeutics Inc — Cash Flow (NASDAQ:HOTH) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Cash from operating activities -6.13 M-12.09 M-9.3 M-8.45 M-6.98 M -9.68 M Cash from investing activities -1.84 M-165.35 K1.16 M0— — Cash from financing activities 8.73 M18.19 M6.04 M11.32 M4.74 M 9.82 M Free cash flow -6.13 M-12.09 M-9.3 M-8.45 M-6.98 M -9.68 M

Notizie

Hoth Therapeutics aggiunge un sito clinico per lo studio sulla tossicità cutanea

Hoth Therapeutics adds clinical site for skin toxicity trial

Esclusiva: Hoth Therapeutics svela l’arma segreta contro i chili di troppo - Benzinga Italia

Il trattamento per l’obesità di Hoth supera il semaglutide in studio preclinico

Hoth’s obesity treatment outperforms semaglutide in preclinical study

EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study - Hoth Therapeutics (NASDAQ:HOTH)

Le azioni di Hoth Therapeutics salgono dopo risultati positivi della sperimentazione

Hoth Therapeutics stock rises after positive interim trial results

Hoth riporta risultati intermedi positivi per terapia cutanea contro il cancro

Hoth reports positive interim results for cancer skin therapy

Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half - Hoth Therapeutics (NASDAQ:HOTH)

Le azioni di Hoth Therapeutics salgono dopo aver ottenuto un brevetto cinese per la terapia contro il cancro